While Alto Neuroscience Inc. has underperformed by -69.99%, investors are advised to look at stock chart patterns for technical insight.
On October 23, 2024, Wedbush Downgraded Alto Neuroscience Inc. (NYSE: ANRO) to Neutral. A report published by Rodman & Renshaw on October 23, 2024, Downgraded its rating to ‘Neutral’ for ANRO. Wedbush also rated ANRO shares as ‘Outperform’, setting a target price of $29 on the company’s shares in an initiating report dated September 03, 2024. TD Cowen initiated its ‘Outperform’ rating for ANRO, as published in its report on February 27, 2024. Stifel’s report from February 27, 2024 suggests a price prediction of $32 for ANRO shares, giving the stock a ‘Buy’ rating. Robert W. Baird also rated the stock as ‘Outperform’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Alto Neuroscience Inc. (ANRO)
In order to gain a clear picture of Alto Neuroscience Inc.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. Taking into account the quick ratio of the company, currently set at 19.85, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 364.56K can be a very valuable indicator of volatility for ANRO stock. On a monthly basis, the volatility of the stock is set at 7.87%, whereas on a weekly basis, it is put at 11.36%, with a loss of -69.83% over the past seven days. Furthermore, long-term investors anticipate a median target price of $16.41, showing growth from the present price of $4.36, which can serve as yet another indication of whether ANRO is worth investing in or should be passed over.
How Do You Analyze Alto Neuroscience Inc. Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.74%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 68.21% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ANRO shares are owned by institutional investors to the tune of 68.21% at present.
